References
- Molodecky NA, Soon IS, Rabi DM, William A. Ghali WA, Ferris M, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastro. 2012;142:46-54. https://doi.org/10.1053/j.gastro.2011.10.001
- Yang SK, Yun SC, Kim JH, Park JY, Kim HY, Kim YH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis. 2008;14:542-549. https://doi.org/10.1002/ibd.20310
- Lee J. Fecal calprotectin in inflammatory bowel disease. Korean J Gastroenterol. 2016;67:233-237. http://doi.org/10.4166/kjg.2016.67.5.233
- Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinskas L, Geboes K, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006;55:1-15. https://doi.org/10.1136/gut.2005.081950a
- Cobb WS, Heniford BT, Sigmon LB, Hasan R, Simms C, Kercher KW, et al. Colonoscopic perforations: incidence, management, and outcomes. Am Surg. 2004;70:750-757; discussion 757-758.
- Sutherland AD, Gearry RB, Frizelle FA. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum. 2008;51:1283-1291. https://doi.org/10.1007/s10350-008-9310-8
- Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir 1980;16:273-282. https://doi.org/10.1016/B978-0-08-027379-2.50028-4
- Roseth A, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992;27:793-798. https://doi.org/10.3109/00365529209011186
- Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426-431. https://doi.org/doi:10.1136/gut.2005.069476
- Park SH, Kim WJ. A study of fecal calprotectin in obese children and adults. J Obes Metab Syndr. 2018;27:233-237. https://doi.org/10.7570/jomes.2018.27.4.233
- Roseth A, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999;34:50-54. https://doi.org/10.1080/00365529950172835
- Lee YW, Lee KM, Lee JM, Chung YY, Kim DB, Kim YJ et al. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity. Korean J Intern Med. 2019;34:72-80. https://doi.org/10.3904/kjim.2016.324
- Olafsdottir E, Aksnes L, Fluge G, Berstad A: Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr. 2002;91:45-50. https://doi.org/10.1080/080352502753457932
- Josefsson S, Bunn SK, Domellof M. Fecal calprotectin in very low birth weight infants. J Pediatr Gastroenterol Nutr. 2007;44:407-413. https://doi.org/10.1097/mpg.0b013e3180320643
- Yang Q, Smith PB, Goldberg RN, Cotten CM: Dynamic change of fecal calprotectin in very low birth weight infants during the first month of life. Neonatology. 2008;94:267-271. https://doi.org/10.1159%2F000151645 https://doi.org/10.1159/000151645
- Yoon JM, Park JY, Ko KO, Lim JW, Cheon EJ, Kim HJ. Fecal calprotectin concentration in neonatal necrotizing enterocolitis. Korean J Pediatr. 2014;57:351-356. http:/doi.org/10.3345/kjp.2014.57.8.351
- Van Rheenen PF, Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369. https://doi.org/10.1136/bmj.c3369
- Kostas A, Siakavellas SI, Kosmidis C, Takou A, Nikou J, Maropoulos G et al. Fecal calprotectin measurement is a marker of shortterm clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World Gastroenterol. 2017;23:7387-7396. https://doi.org/10.3748/wjg.v23.i41. 7387
- Lee YW, Lee KM, Lee JM, Chung YY, Kim DB, Kim YJ, et al. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity. Korean J Intern Med. 2019;34;72-80. https://doi.org/10.3904/kjim.2016.324
- Yoo IH, Cho JM, Joo JY, Yang H. Fecal calprotectin as a useful non-invasive screening marker for eosinophilic gastrointestinal disorder in Korean children. J Korean Med Sci. 2020;35:e120. https://doi.org/ 10.3346/jkms.2020.35.e120
- Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Inflamm Bowl Dis. 2009;15:1746-1754. https://doi.org/10.1002/ibd.20920
- Seo SC, Ahn SH, Ri SH, Yoon YS, Byeon JH, Kim SH et al. Elevated fecal calprotectin levels are associated with severity of atopic dermatitis in children. Asian Pac J Allergy Immunol. 2018;36:82-87. https://doi.org/10.12932/ap-100317-0044
- Mumolo MG, Bertani L, Ceccarelli L, Laino G, Di Fluri G, Albano E, et al. From bench to bedside: fecal calprotectin in inflammatory bowel diseases clinical setting. World J Gastroenterol. 2018;24:3681-3694. http://doi.org/10.3748/wjg.v24.i33.3681
- Rogler G, Aldeguer X, Kruis W, Lasson A, Mittmann U, Nally K, et al. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion. J Crohns Colitis. 2013;7:670-677. https://doi.org/10.1016/j.crohns.2013.02.014
- Zhu Q, Li F, Wang J, Shen L, Sheng X. Fecal calprotectin in healthy children aged 1-4 years. PLoS One. 2016;11:1-10. https://doi.org/10.1371/journal.pone.0150725
- Elin H, James KT, Thorkild T, Lena G, Grace N, Deogratias HKM, et al. Fecal calprotectin concentrations in apparently healthy children aged 0-12 years in urban kampala, Uganda: a community-based survey. BMC Pediatrics. 2011;11;9-16. http://doi.org/10.1186/1471-2431-11-9
- Li F, Ma J, Geng S, Wang J, Liu J, Zhang J, et al. Fecal calprotectin concentrations in healthy children aged 1-18 months. PLoS One. 2015;10:e0119574. http://doi.org/10.1371/journal.pone.0119574
- Joshi S, Lewis SJ, Creanor S, Ayling RM. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem. 2010;47:259-263. http://doi.org/10.1258/acb.2009.009061
- Leonardil GC, Accardi G, Monastero R, Nicoletti F, Libra M. Ageing: from inflammation to cancer. Immun Ageing. 2018;15:1. https://doi.org/10.1186/s12979-017-0112-5
- Poullis A, Foster R. Shetty A, Fagerhol MK, Mendall MA. Bowel inflammation as measured by fecal calprotectin. Cancer Epidemiol Biomarkers Prev. 2004;13;279-284. https://doi.org/10.1158/1055-9965.epi- 03-0160